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Abstract
Background: Disease prevention has been claimed to reduce health care costs. However, preventing lethal diseases
increases life expectancy and, thereby, indirectly increases the demand for health care. Previous studies have argued that on
balance preventing diseases that reduce longevity increases health care costs while preventing non-fatal diseases could
lead to health care savings. The objective of this research is to investigate if disease prevention could result in both
increased longevity and lower lifetime health care costs.
Methods: Mortality rates for Netherlands in 2009 were used to construct cause-deleted life tables. Data originating from the
Dutch Costs of Illness study was incorporated in order to estimate lifetime health care costs in the absence of selected
disease categories. We took into account that for most diseases health care expenditures are concentrated in the last year of
life.
Results: Elimination of diseases that reduce life expectancy considerably increase lifetime health care costs. Exemplary are
neoplasms that, when eliminated would increase both life expectancy and lifetime health care spending with roughly 5%
for men and women. Costs savings are incurred when prevention has only a small effect on longevity such as in the case of
mental and behavioural disorders. Diseases of the circulatory system stand out as their elimination would increase life
expectancy while reducing health care spending.
Conclusion: The stronger the negative impact of a disease on longevity, the higher health care costs would be after
elimination. Successful treatment of fatal diseases leaves less room for longevity gains due to effective prevention but more
room for health care savings.
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Introduction
Worldwide ageing of populations is perceived as a threat to the
global economy. One major consequence of ageing is claimed to
be a rising proportion of GDP spent on health care. Population
ageing refers to an increase in the number of old persons relative
to the number of young persons, especially those aged 80 and
above [1]. The main causes of population ageing are a decrease in
fertility and an increase in life expectancy (increased longevity). To
counter growing health care costs from ageing, it has been put
forward that disease prevention might decrease disease-related
costs [2]. Indeed, preventing a disease would avoid costs aimed at
that particular disease and therefore could result in decreased
health care costs in the short run. However, prevention of some
diseases will increase longevity. Then, people will (ceteris paribus)
consume more health care since the additional years are, on
average, spent in less than ideal health [3]. To what extent the
additional health care costs in ‘added’ life years outweigh savings
in ‘normal’ years differs per disease and type of preventive
intervention [4,5]. Diseases associated with a high mortality risk
have a strong negative impact on longevity, especially if these
diseases have an early age of onset. The situation is different with
chronic or disabling diseases [6]. Persons who attract such diseases
can often live close to the average life expectancy. Nevertheless,
chronic diseases may cause a reduction in quality of life and bring
about continuous need for health care services.
Two decades ago, Bonneux and colleagues [7] investigated
what would happen to Dutch expected lifetime health care costs in
the hypothetical situation that certain diseases are eliminated.
They found an inverse relation between degree of fatality and
costs. This implies that disease-related costs for highly fatal
diseases, such as coronary heart disease and cancer, account for
only a small percentage of total health care costs, while diseases
with a low mortality rate, such as mental disorders, account for a
substantial part of the allocated health care budget. The study
concluded that in countries with low mortality rates, elimination of
fatal diseases through successful prevention increases health care
costs due to medical expenses during life years gained. These
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findings indicated that prevention targeted at risk factors related to
lethal diseases such as smoking, and to a lesser extent obesity,
might not result in savings in medical costs [4,5]. Since Bonneux
and colleagues’ study three important variables have changed.
First, the statistics of primary causes of death have changed.
Compared to two decades ago, mortality rates of the Dutch
population have declined [8]. More specifically, mortality rates
from coronary heart disease have halved for both sexes [9]; for
patients admitted with myocardial infarction mortality rates have
gone down by two-thirds [10]. Second, the Dutch costs of illness
have risen each year [11]. Third, new insights into the effect of
increased longevity on health costs have been developed.
Traditionally, it was believed that increased longevity would
strongly increase the demand for health care as average health
care costs rise sharply with age. However, focussing only on age,
sex and disease ignores a crucial element know as proximity or
time to death. Zweifel and colleagues [1], and later Seshamani and
Gray [12], explain that proximity to death is more crucial to the
level of individual medical costs than age. The terminal phase of
life is expensive whenever it occurs. As mortality increases with
age, average health care costs also increase with age. However,
costs per care provider category are affected differently by the
effect of time to death. Long-term care costs for people who
already make use of this type of care increase with age, regardless
of time to death [13]. Also, the effect of time to death on health
care costs differs per disease and is strongest for most types of
neoplasms [14].
This study investigates the differential effects of prevention on
longevity and lifetime health care costs. In particular, it sheds light
on the relationship between disease-fatality and the potential of
prevention to lower health care costs. We adopt a similar approach
to Bonneux and colleagues, using more recent mortality and cost
data and take proximity to death into account
Methods
This research used life table techniques to calculate life
expectancy (LE), both standard LE (including all causes of death)
and cause-deleted LE (where specific causes of death are deleted)
in relation to lifetime health care costs. Cause-deleted life tables
show what a cohort’s life expectancy and associated health care
costs would be when no person dies from a particular disease
(Primary Cause of Death (PCoD). In total 24 life tables were
constructed for different diseases and disease categories. Data on
mortality and population size was collected from Statline, the
online database from Statistics Netherlands. To compare the
results of this study to those of Bonneux and colleagues [7], we
used the ICD-9 codes of the PCoDs from Statline to combine the
primary causes into (mutually exclusive) disease categories. Similar
to Bonneux and colleagues we used the disease categories of the
Cost of Illness (COI) studies. In those studies total direct health
care costs in different health care settings in the Netherlands are
uniquely attributed to 107 diseases specified by gender and age
[15]. For comparative purposes, a number of single diseases were
added that were also incorporated by Bonneux and colleagues.
Estimates of life expectancy and lifetime health care costs from
the cause-deleted life tables were compared to the all cause life
table. Although complete elimination of a disease is almost never
attainable, the relevant mechanisms of disease prevention are the
same whether or not elimination is total or partial. Moreover, it
enhances the visibility of the mechanisms at work as well as the
ease of calculation, since cause-specific mortality then is zero.
Mortality probabilities denoted q in the absence of disease(s) z,
needed to construct cause deleted life expectancy were calculated
in the following manner:
q(a,z)~1{exp½
X
i =[Z
D(a,i)=N(a) ð1Þ
Where q a,zð Þ is the mortality probability at age a in the absence of
disease (group) z, i an index for diseases and D(a,i) the number of
deaths from cause i at age a and N(a) the average population at
age a. Data on the number of deaths was available in (5-year) age
intervals for the year 2009 [16]. In order to construct a full life
table and to retain most data precision, the cause specific mortality
data had to be converted into single-year mortality rates.
Average annual health care costs c at age a in the absence of
disease (group) z were calculated in the following manner;
c a,zð Þ~q a,zð Þ|
X
i =[Z
dc a,ið Þz 1{q a,zð Þ½ |
X
i =[Z
sc a,ið Þ ð2Þ
Where dc a,zð Þ denotes average health care costs at age a for
those who die at that age (excluding costs associated with disease
group z) and, similarly, sc a,zð Þ denotes average annual health care
costs for those who survive at age a (again excluding costs
associated with disease group z).
Equation (2) shows that average costs c a,zð Þ are a weighted
average of the costs of people who die at a particular age and those
who die at a later age. Elimination of a disease affects average
health care costs at a given age in two different ways. First, it
affects the sums of dc a,zð Þ andsc a,zð Þ over all diseases as the costs
of that disease (group) are excluded. Second, there is an indirect
effect through the influence on q a,zð Þ.As costs in the last year of
life dc a,zð Þ are higher than in other years, a decrease in the
mortality probability due to elimination of a disease decreases
average health care costs at that age. However, as the relation
between health care costs and the last year of life differs per disease
there might be complex interactions.
Data on health care costs (dc(a,z)andsc(a,z) came from
software package PAID 1.0 (Practical Application to Include
Disease Costs) [17]. PAID is a toolkit that enables researchers to
estimate future medical costs by calculating annual per capita
health care costs stratified by disease, age, sex and proximity to
death. As a backbone for PAID 1.0, data from the Costs of Illness
(COI) study for the Netherlands from were used [15]. In that study
total direct health care costs in different health care settings in the
Netherlands in 2005 are uniquely attributed to 107 diseases
specified by gender and age.The COI study includes spending on
ambulatory care, hospital care, medication as well as spending on
long term care. Using data from other studies [14] these annual
age, gender and disease specific health care expenditures per
capita are partitioned into annual per capita expenditure in the
last year of life and all other years for all diseases (for details see
[17]). PAID 1.0 consists of a series of worksheets in Excel in which
diseases can be selected (free download at www.bmg.eur.nl/
personal/vanbaal/paid.http). Cause deleted life expectancy le zð Þ
and lifetime health care costs lc(z) were then estimated in the
following manner:
le(z)~
X100
x~0
Pxj~0 ½1{q(a~j,z) ð3Þ
lc(z)~
X100
x~0
c(a,z)|Pxj~0 ½1{q(a~j,z) ð4Þ
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Results
In this paper, for legibility, only the results for the most
noticeable disease categories and one single disease, relevant for
the discussion, are shown (the full tables are presented as
supplementary material: Table S1 contains all results for men
and Table S2 contains all results for women). The tables, one for
men (table 1) and one for women (table 2), include all values of, as
well as absolute and relative changes in, life expectancy and
lifetime health care costs, subdivided into health care sectors such
as hospital care, as well as the aggregate.
Taking the all-cause life table as a base case, the disease
categories that would result in the greatest increases in longevity, if
eliminated, were for both sexes ‘‘neoplasms’’ (+4.1 and +3.6 years
for men and women respectively) and ‘‘diseases of the circulatory
system’’ (+3.0 and +2.9 years for men and women respectively).
The disease category that would result in lowest lifetime health
care costs if eliminated is (with the values in thousands of Euros in
parentheses) ‘‘mental and behavioural disorders’’ (J36,700 and
J58,200 lower for men and women respectively). The only
category that would result in higher lifetime health care costs if
eliminated is ‘‘neoplasms’’ (J16,300 and J16,900 higher for men
and women respectively). However, at the level of subcategories,
we also identified a disease category which, if eliminated, would
result in higher lifetime health care costs: coronary heart disease
for women (2 J3,300 and +J600 for men and women
respectively). This finding will be explained in the discussion
section.
The cost results have thus far been described in aggregate. More
insight into the mechanisms through which prevention impacts on
health care costs is gained by considering the distribution of costs
over the different provider categories. Elimination of highly fatal
diseases, such as ‘neoplasms’, results in a decrease in ‘‘hospital
care’’ costs, but a large increase in ‘‘nursing and residential care
facilities’’. In contrast, eliminating ‘‘mental and behavioural
disorders’’ would result in savings both in ‘‘hospital care’’ and
‘‘nursing and residential care facilities’’. Costs on ‘‘nursing home
and residential care’’ increase with elimination of acute and fatal
diseases (e.g. neoplasms), and decreases with chronic and less fatal
diseases (e.g. mental and behavioural disorders). Costs on
‘‘providers of ambulatory health care’’, ‘‘retail sale and other
providers of medical goods’’ and ‘‘other health care providers’’
changed less than the other two provider categories.
Discussion
The results of this research show that elimination of fatal
diseases would lead to increased longevity as well as higher lifetime
health care costs. Thereby, our findings confirm for a large part
the results of the study of Bonneux and colleagues [7]: in the
Netherlands, elimination of fatal diseases would increase health
care costs and elimination of non-fatal diseases would lower
lifetime health care costs. However, there are some differences in
our findings due to temporal changes in primary causes of death
and costs of illness. For instance, as costs of mental and
behavioural disorders have risen, potential savings have increased.
Moreover, we also used a somewhat different method to estimate
lifetime health care costs, taking into account research emphasiz-
ing the relevance of time to death.
Most important, Bonneux and colleagues found that elimination
of ‘‘diseases of the circulatory system’’ would result in higher
lifetime health care costs (+5.2% for men and +10.7% for women)
and in our study that would result in lower costs (25.1% for men
and 21.9% for women). Also, they found increases in longevity
with that elimination as great as a 7.1% increase for men and a
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6.3% increase for women, though in this research it resulted in
more moderate increases of 3.0% and 2.9% for men and women
respectively.
The changes over time indicate that potential increases in
longevity decrease with elimination of diseases of the circulatory
system, whereas lifetime health care costs saw a change from
higher to lower costs. This can be explained by a change on the
scale from acute to chronic: the availability of more effective
treatments for circulatory diseases has resulted in increased
survival (and reduced marginal gains), but also higher costs.
Successful treatment of fatal diseases thereby diminishes the
potential for achieving increases in longevity by prevention, while
at the same time it creates opportunities to spend less on health
care.
The added value of the results of this research lies in a number
of areas. First, this study was built on more recent Dutch
epidemiological and cost data, providing an up to date view on life
expectancy and lifetime health care costs in the Netherlands.
Second, a comprehensive range of diseases and disease categories
were included, making comparisons possible both across diseases
and across time. Third, as mentioned above, the relevance of time
to death was explicitly dealt with in the methods of calculation. In
a sensitivity analysis we calculated lifetime health costs without
incorporating time to death. By neglecting the mechanism that for
most diseases health care expenditures are concentrated in the last
year of life two diseases (COPD and coronary heart disease for
women) appeared to induce lower costs if eliminated.
By assuming the improbable situation of total elimination of
diseases, insights can be gained into what the relative benefits and
consequences could be of investing in the prevention of particular
diseases and disease categories. In this regard the gains in life
expectancy as well as the cost implications calculated with the life
tables are at the extremes of the spectrum of what effective
preventative interventions can achieve. The results highlight that
the lethality of a disease is a crucial factor influencing these
variables. In this respect, an important potential confounding
factor should be mentioned, namely the uncertainty surrounding
the attribution of a specific cause of death. When physicians
determine the primary cause of death, this is often not based on a
full-scale autopsy. This gives room to differences in interpretations
and confounds the validity of the data. Also, it is often difficult to
determine ‘the real’ cause of death, when several interrelated
potential causes are at work, such as in the case of a complex
disease such as heart failure [18]. More importantly, many
preventive interventions are not targeted at single diseases, but
rather at risk factors that are related to a variety of diseases.
Consequently, results for specific intervention measures would
depend on that mix [5]. Although our findings facilitate a better
understanding of these interventions, separate analyses should be
carried out to quantify gains. While a risk factor like smoking is
strongly related to several lethal diseases, this is not the case for a
risk factor like obesity that is also related to non-fatal diseases that
are highly prevalent.
A potential limitation of this study is that we could not take into
health care costs outside of the health care setting, which might
have biased our findings. In particular, for instance treatment for
mental health problems could save on long term healthcare
expenditures with only a small effect on life expectancy. It should
be noted, however, that the expenditure data we used include
expenditures on long term care facilities. As in the Netherlands,
long term care facilities are quite generous in comparison with
other developed countries and to a large extent publicly financed
[19], we do not think that including health care spending outside
the health care setting would have a big impact on our findings.
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Out-of-pocket health care spending is very low in the Netherland
compared to other countries. Only spending on informal care is
not included in our calculations. However, as the level of formal
care is quite high in the Netherlands we expect the influence of this
to be limited. Yet, this limitation should be taken into account
when extrapolating the results to health care systems in other
countries.
The findings of this study lead us to three concluding remarks.
First, the results can help policy makers and researchers evaluate
the possible effects of preventive measures on both longevity and
health care costs. Second, the evolution of diseases of the
circulatory system such as coronary heart disease, from a disease
(category) that, if eliminated, would increase lifetime health care
costs to one that would decreases it, points to a very important
mechanism mediating the effects of disease prevention. There is an
interaction between preventive and curative healthcare. The more
effective curative care is, the more it reduces the potential health
gains of preventative care. On the other hand, it simultaneously
opens a window of opportunity for reducing health care costs. This
should make prevention a very interesting policy aim and also a
profitable direction for insurers [20]. For researchers the
interaction between preventive and curative care is relevant for
correctly estimating lifetime healthcare costs because otherwise the
effect of prevention on cost-effectiveness may be overestimated.
For example, Lansdorp-Vogelaar and colleagues [21] assume that
costs of treating colorectal cancer will increase and therefore
prevention becomes more cost effective. However, rising invest-
ments on curative interventions for colorectal cancer improve the
prospects of patients and therewith decrease the potential health
gains of prevention. This leads to a new paradox: successful
treatment of fatal diseases leaves less room for life expectancy gains
due to effective prevention but more room for health care savings.
On a third and final note, increasing longevity is not the only aim
of disease prevention. The other very important goal is improving
quality of life. Therefore, it would be interesting to perform
additional research that includes measures of quality of life into the
life tables. This would give a more complete picture of the
mechanisms of disease prevention and its potential effects.
Especially for non-fatal diseases health benefits of prevention are
underestimated if one focuses on length of life only and ignores
benefits in terms of quality of life. However, here, we expect
similar mechanisms as with health care expenditures. While for
diseases that do not strongly decrease longevity it suffices to look at
quality of life losses for that disease only, in the case of lethal
diseases it is important to look both at quality of life losses and life
years lost.
Concluding, the stronger the negative impact of a disease on
longevity, the higher health care costs would be after hypothetical
elimination of that disease. Successful treatment of fatal diseases
leaves less room for longevity gains due to effective prevention, but
more room for health care savings.
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